Radiotherapy of Hodgkin Lymphoma: Indications, New Fields, and Techniques

Seminars in Radiation Oncology

Volumn 17, Issue 3, 2007, Pages 206-222

  Girinsky, Theodore ^a   Ghalibafian, Mithra ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; HODGKIN DISEASE; HUMAN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; TUMOR REGRESSION;

CHEMOTHERAPY, ADJUVANT; HODGKIN DISEASE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; REMISSION INDUCTION; RISK ASSESSMENT; TECHNOLOGY, RADIOLOGIC; TREATMENT OUTCOME;

EID: 34250697156     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2007.02.007     Document Type: Article

References (78)

1. Aleman B.M.P., van den Belt-Dusebout A.W., and Klokman W.J. Long-term cause-specific mortality of patients treated for Hodgkin disease. J Clin Oncol 21 (2003) 3431-3439
2. Bhatia S., Robison L.L., and Oberlin O. Breast cancer and other second neoplasms after childhood Hodgkin disease. N Engl J Med 334 (1996) 745-751
3. Hancock S.L., Tucker M.A., and Hoppe R.T. Factors affecting late mortality from heart disease after treatment of Hodgkin disease. JAMA 270 (1993) 1949-1955
4. Koontz F., Kirkpatrick P., and Clough W. Combined modality therapy versus radiotherapy alone for treatment of early stage Hodgkin disease: Cure versus complications. J Clin Oncol 24 (2005) 605-611
5. Mauch P. Second malignancies after curative radiation therapy for good prognosis cancers. Int J Radiat Oncol Biol Phy 33 (1995) 959-960
6. Ng A.K., Bernardo M.P., and Weller E. Long-term survival and competing causes of death in patients with early-stage Hodgkin disease treated at age 50 or younger. J Clin Oncol 20 (2002) 2101-2108
7. van Leeuwen F.E., Klokman W.J., and Stovall M. Role of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95 (2003) 971-980
8. Longo D.L. Radiation therapy in the treatment of Hodgkin disease-Do you see what I see?. J Natl Cancer Inst 95 (2003) 928-929
9. Klimm B., Diehl V., and Pfistner B. Current strategies of the German Hodgkin Study Group (GHSG). Eur J Haematol 75 suppl 66 (2005) 125-134
10. Ferme C., Eghbali H., and Hagenbeek A. MOPP/ABV (M/A) hybrid and irradiation in unfavourable supradiaphragmatic clinical stages I-II Hodgkin disease: comparison of three treatment modalities. Preliminary results of the EORTC-GELA H8-U randomised trial in 995 patients. Blood 96 (2000) 576 (abstr 2473)
11. Noordijk E.M., Thomas J., and Ferme C. First results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable and unfavourable early stage Hodgkin lymphoma. Proc Am Soc Clin Oncol 124 (2005) abstr 6505
12. Hasenclever D., and Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin disease. N Engl J Med 339 (1998) 1506-1514
13. Noordijk E.M., Carde P., and Dupouy N. Combined-modality therapy for clinical stage I or II Hodgkin lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials. J Clin Oncol 24 (2006) 3128-3135
14. Press O.W., LeBlanc M., and Lichter A.S. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin disease. J Clin Oncol 19 (2001) 4238-4244
15. Sieber M., Franklin J., and Tesch H. Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin' s disease: Results of the German Hodgkin lymphoma Study Group (GHSG) trial HD7. Blood 100 (2002) 93 (abstr 341)
16. Hagenbeek A., Eghbali H., and Ferme C. Three cycles of MOPP/ABV (M/A) hybrid and involved-field irradiation is more effective than subtotal nodal irradiation (STNI) in favorable supradiaphragmatic clinical stage (CS) I-II Hodgkin disease (HD): Preliminary results of the EORTC-GELA trial in 543 patients. Blood 96 (2000) 575 (abstr 2472)
17. Bonadonna G., Bonfante V., and Viviani S. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin disease: Long-term results. J Clin Oncol 22 (2004) 2835-2841
18. Eich H., Mueller R., and Engert A. Comparison of 30 Gy versus 20 Gy involved field radiotherapy after two versus four cycles of ABVD in early stage Hodgkin lymphoma: Interim analysis of the German Hodgkin Study Group Trial HD10. Int J Radiat Oncol Biol Phys 63 (2005) 1-2 (abstr)
19. Diehl V., Brillant C., and Engert A. Investigating reduction of combined-modality treatment intensity in early stage Hodgkin lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSD). Proc Am Soc Clin Oncol 124 (2005) 6506 (abstr)
20. Horning S.J., Hoppe R.T., and Advani R. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin disease: Mature data in early and advanced stage patients. Blood 104 (2004) (abstr 308)
21. Engert A., Schiller P., and Josting A. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavourable Hodgkin lymphoma: Results of the HD8 trial of the German Hodgkin Lymphoma Study Group. J Clin Oncol 21 (2003) 3601-3608
22. Klimm B.C., Engert A., and Brillant C. Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin lymphoma: Results of the fourth interim analysis of the HD-11 trial of the GHSG. Proc Am Soc Clin Oncol 124 (2005) (abstr 6507)
23. Diehl V., Loeffler M., and Pfreundschuh M. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin disease. Ann Oncol 6 (1995) 901-910
24. Laskar S., Gupta T., and Vimal S. Consolidation radiation after complete remission in Hodgkin disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need?. J Clin Oncol 22 (2004) 62-68
25. Yahalom J., Ryu J., and Straus D.J. Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin disease treated with alternating chemotherapy combinations. J Clin Oncol 9 (1991) 2193-2201
26. Fabian C.J., Mansfield C.M., and Dahlberg S. Low-dose involved field radiation after chemotherapy in advanced hodgkin disease. A Southwest Oncology Group Randomized study. Ann Intern Med 120 (1994) 903-912
27. Ferme C., Mounier N., and Casasnovas O. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 107 (2006) 4636-4642
28. Brice P., Colin P., and Berger F. Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy. Cancer 92 (2001) 453-459
29. Aleman B.M.P., Raemaekers J.M.M., and Tirelli U. Involved-field radiotherapy for advanced Hodgkin lymphoma. N Engl J Med 348 (2003) 2396-2406
30. Loeffler M., Brosteanu O., and Hasenclever D. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin disease. J Clin Oncol 16 (1998) 818-829
31. Duggan D.B., Petroni G.R., and Johnson J.L. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin disease: Report of an Intergroup Trial. J Clin Oncol 21 (2003) 607-614
32. Canellos G.P., and Niedzwiecki D. Long-term follow-up of Hodgkin disease trial. N Engl J Med 346 (2002) 1417-1418
33. Horning S.J., Hoppe R.T., Breslin S., et al. Radiotherapy for locally extensive and advanced Hodgkin disease: Mature results of a prospective clinical trial. J Clin Oncol 2 (2002) 630-637
34. Fabian C., Dahlberg T., and Miller S. Efficacy of low dose involved field (LDIF) XRT in producing and maintening CR following PR induction with MOP-BAP chemotherapy in Hodgkin disease: Results of the Southwest Oncology Group Study 7808. Proc Am Soc Clin Oncol 8 (1989) 253 (abstr)
35. Aleman B.M.P., Raemakers J.M.M., and Tomsic R. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 67 (2007) 19-30
36. Martens C., Hodgson D.C., and Wells W.A. Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 64 (2006) 1183-1187
37. Girinsky T., Lapusan S., and Ribrag V. Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas. Int J Radiat Oncol Biol Phys 61 (2005) 476-479
38. Yahalom J., Gulati S.C., and Toia M. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for refractory and relapsing patients with Hodkgin's disease. J Clin Oncol 11 (1993) 1062-1070
39. Poen J.C., Hoppe R.T., and Horning S.J. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin disease: The impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys 61 (2005) 476-479
40. Travis L.B., Hill D., and Dores G.M. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 97 (2005) 1428-1436
41. Salloum E., Doria R., and Schubert W. Second solid tumors in patients with Hodgkin disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 14 (1996) 2435-2443
42. Longo D.L. Radiation therapy in Hodgkin disease: Why risk a Pyrrhic victory?. J Natl Cancer Inst 97 (2005) 1394-1395
43. Londo D.L. Hodgkin disease: The sword of Damocles resheathed. Blood 104 (2004) 3418
44. Franklin JG, Paus MD, Pluetschow A: Chemotherapy, radiotherapy and combined modality for Hodgkin disease with emphasis on second cancer risk. The Cochrane Collaboration. Cochrane Library, Eds Wiley, issue 2, 2006
45. Straus D.J., Portlock C.S., and Qin J. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104 (2004) 3483-3489
46. Pavlovsky S., Maschio M., and Santarelli M.T. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin disease. J Natl Cancer Inst 80 (1988) 1466-1473
47. Meyer R.M., Gospodarowicz M.K., and Connors J.M. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23 (2005) 4634-4642
48. Shahidi M., Kamangari N., and Ashley S. Site of relapse after chemotherapy alone for stage I and II Hodgkin disease. Radiother Oncol 78 (2006) 1-5
49. Nachman J.B., Sposto R., and Herzog P. Randomized comparison of low-dose involved- field radiotherapy and no radiotherapy for children with Hodgkin disease who achieve a complete response to chemotherapy. J Clin Oncol 20 (2002) 3765-3771
50. Martin W.G., Ristow K.M., and Habermann T.M. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin lymphoma. J Clin Oncol 23 (2005) 7614-7620
51. Doyle J.J., Neugut A.I., and Jacobson J.S. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 23 (2005) 8597-8605
52. Aviles A., Neri N., and Nambo J.M. Late cardiac toxicity secondary to treatment in Hodgkin disease. A study comparing doxorubicin, epirubicin, and mitoxantrone in combined therapy. Leuk Lymphoma 46 (2005) 1023-1028
53. Moser E.C., Noordijk E.M., and van Leeuwen F.E. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 107 (2006) 2912-2919
54. Donaldson S.S., Hudson M.M., and Lamborn K.R. VAMP and low dose, involved- field radiation for children and adolescents with favorable, early-stage Hodgkin disease: Results of a prospective clinical trial. J Clin Oncol 20 (2002) 3081-3087
55. Landman-Parker J., Pacquement H., and Leblanc T. Localized childhood Hodgkin disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine and prednisone before low-dose radiation therapy. Results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 18 (2000) 1500-1507
56. van Leeuwen F.E., Klokman W.J., and van't Veer M.B. Long-term risk of second malignancy in survivors of Hodgkin disease treated during adolescence or young adulthood. J Clin Oncol 18 (2000) 487-497
57. Andre M., Mounier N., and Leleu X. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: A GELA cohort study on 2837 patients. Blood 103 (2004) 1222-1228
58. Yahalom J. Don't throw out the baby with the bathwater: On optimizing cure and reducing toxicity in Hodgkin lymphoma. J Clin Oncol 24 (2006) 544-548
59. Carde P., Koscielny S., and Franklin J. Early response to chemotherapy: A surrogate for final outcome of Hodkgin's disease patients that should influence initial treatment length and intensity ?. Annals Oncol 13 suppl 1 (2002) 89-91
60. Kung F.H., Schwartz C.L., and Ferree C.R. POG 8625: A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stage I, IIA, IIIA1, Hodgkin disease: A report from the Children's Oncology Group. J Pediatr Hematol Oncol 28 (2006) 362-368
61. Rühl U., Albrecht M., and Dieckmann K. Response-adapted radiotherapy in the treatment of pediatric Hodgkin disease: An interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 51 (2001) 1209-1218
62. Weiner M.A., Leventhal B., and Brecher M.L. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal irradiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin disease in Pediatric patients: A Pediatric Oncology Group Study. J Clin Oncol 15 (1997) 2769-2779
63. Kuentz M., Reyes F., and Brun B. Early response to chemotherapy as a prognostic factor in Hodgkin disease. Cancer 52 (1983) 780-785
64. Hutchings M., Loft A., and Hansen M. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 (2006) 52-59
65. Gallamini A., Rigacci L., and Merli F. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin disease. Haematologica 91 (2006) 475-481
66. Jerusalem G., and Beguin Y. The place of positron emission tomography imaging in the management of patients with malignant lymphoma. Haematologica 91 (2005) 442-444
67. Mudie N.Y., Swerdlow A.J., and Higgins C.D. Risk of second malignancy after non-Hodgkin lymphoma: A British Cohort Study. J Clin Oncol 24 (2006) 1568-1574
68. Chronowski G.M., Wilder R.B., and Tucker S.L. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys 55 (2003) 36-43
69. Specht L., Gray R.G., and Clarke M.J. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin disease: A meta- analysis of 23 randomized trials involving 3 888 patients. J Clin Oncol 16 (1998) 830-843
70. Yahalom J., and Mauch P. The involved field is back: Issues in delineating the radiation field in Hodgkin disease. Ann Oncol 13 suppl 1 (2002) 79-83
71. Girinsky T., van der Maazen R., and Specht L. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. Radiother Oncol 79 (2006) 270-277
72. ICRU: Prescribing, recording and reporting photon beam therapy. Report 50. International Commission on Radiation Units and Measurements. Washington DC, 1993
73. Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma: New concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol 75 suppl 66 (2005) 90-97
74. Goodman K.A., Toner S., and Hunt M. Intensity modulated radiation therapy in the treatment of lymphoma involving the mediastinum. Int Radiat Oncol Biol Phys 62 (2005) 192-206
75. Girinsky T., Pichenot C., and Beaudre A. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-conformal radiotherapy for mediastinal masses in patients with Hodgkin disease, and is there a role for beam orientation optimisation and dose constraints assigned to virtual volumes?. Int J Radiat Oncol Biol Phys 64 (2006) 218-226
76. Duan J., Shen S., and Fiveash J.B. Dosimetric and radiobiological impact of dose fractionation on respiratory motion induced IMRT delivery errors: A volumetric dose measurement study. Med Phys 33 (2006) 1380-1387
77. Fowler J.F., Welsh J.S., and Howard S.P. Loss of biological effect in prolonged fraction delivery. Int J Radiat Oncol Biol Phys 59 (2004) 242-249
78. Brincker H., and Bentzen S.M. A re-analysis of available dose-response and time-dose data in Hodgkin disease. Radiother Oncol 30 (1994) 227-230